Insulet stock heads into the open after a flat Nasdaq close

At the close on September 18, 2026, Insulet stock finished at USD 140.60 on Nasdaq with a negligible percent move, holding within its recent trading range while the broader market posted modest gains. Today, investors watch credit agreement changes disclosed in a fresh 8-K filing.

Insulet stock closed at USD 140.60 on Nasdaq on September 18, 2026, with a negligible percent change versus the prior close. Compared with the broader market, the shares held steady while major United States equity indices posted modest gains that day.

September 18, 2026 in numbers

Insulet Corporation (ISIN US45784P1012, Nasdaq: PODD) last closed at USD 140.60 on Nasdaq on September 18, 2026, according to data cited by Ad-hoc-news. That session price sat within the stock's recent trading band and provided the latest reference level in United States dollars for investors tracking the name. The cited report noted that the shares opened and closed at the same level, implying very limited intraday movement on September 18, 2026, and a flat outcome versus the prior close for that Nasdaq session. Against the backdrop of modest gains in major indices, this stable performance meant Insulet neither significantly outperformed nor underperformed the wider market on that date.

Credit amendment shapes today

Today, attention turns to balance sheet developments after Insulet disclosed changes to its lending arrangements in a recent regulatory filing. As StockTitan reported based on the company’s latest Form 8-K, Insulet entered into a Ninth Amendment to its Credit Agreement dated May 4, 2021 on September 21, 2026, refinancing approximately USD 475 million of loans and adjusting its credit line. The updated agreement with lenders and the administrative agent Morgan Stanley Senior Funding Inc. could influence perceptions of the company’s funding flexibility and interest expense profile heading into today’s United States session. Market participants also continue to monitor broader equity sentiment, with recent coverage such as a wrap from Zacks highlighting choppy index performance in late September 2026, a backdrop that can affect healthcare and medical technology stocks like Insulet today.